Tixagevimab and Cilgavimab Injection, 600 mg

Indiana rates for HCPCS Q0221

Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 600 mg

Rates data updated July 2026.

How much rates vary

Facilitymedian $63,096 · 10th to 90th $63,096 to $70,795

Distribution of negotiated rates across all payers (price axis is log-scale). Each curve is scaled to its own total: facility and professional rates are different services, shown together to compare where they cluster. Small sample; interpret with caution. Need provider-level prices or 24+ months of history? Contact us.

Rates by insurance carrier

Insurance Carrier	Facility/Professional	Modifier	Typical Low	Median	Typical High
CareSource Setting Facility Modifier Global Typical Low $63,095.73 Median $63,095.73 Typical High $70,794.58	Facility	Global	$63,095.73	$63,095.73	$70,794.58